Lec. 1+2 - Nephrolithiasis.pdf

Nephrolithiasis Dr. Montadher Al-Madani 31-3-2016
4-4-2016
2 ©Ali Kareem 2015-2016
Nephrolithiasis
Composition of Renal Stones
1. Calcium oxalate (dihydrate and monohydrate): 70%.
2. Calcium phosphate (hydroxyapatite): 20%.
3. Mixed calcium oxalate and calcium phosphate: 11% to 31%.
4. Uric acid: 8%.
5. Magnesium ammonium phosphate (struvite): 6%.
6. Cystine: 2%.
7. Miscellaneous: xanthine, silicates, and drug metabo- lites, such as
indinavir (radiolucent on x-ray and CT scan).
Pathogenesis and Physiochemical Properties
GENETICS
1. Idiopathic hypercalciuria
o Polygenic
o Calcium salt stones
o Rare nephrocalcinosis
o Rare risk of end-stage renal disease
2. Primary hyperoxaluria types 1, 2, and 3
o Autosomal recessive
o Pure monohydrate calcium oxalate stones (whewellite)
o Nephrocalcinosis
o Risk of end-stage renal disease
3. Distal renal tubular acidosis (RTA)
o Autosomal recessive or dominant
o Apatite stones
o Nephrocalcinosis
4. Cystinuria
o Autosomal recessive associated with a defect on chromosome 2

4-4-2016
3 ©Ali Kareem 2015-2016
o Cystine stones
o No nephrocalcinosis
5. Lesch-Nyhan syndrome (HGPRT deficiency)
o X-linked recessive
o Uric acid stones
o No nephrocalcinosis
ENVIRONMENTAL
1. Dietary factors
o Normal dietary calcium intake is associated with a reduced risk of
calcium stones secondary to binding of intestinal oxalate.
o Increased calcium and vitamin D supplementation may increase
the risk of calcium stones.
o Increased dietary sodium intake is associated with an increased
risk of calcium and sodium urinary excretion, which leads to
increased calcium stones.
o Increased dietary animal protein intake may lead to increased
uric acid and calcium stones.
o Increased water intake is associated with a reduced risk of all
types of kidney stones.
2. Obesity
o Obesity and weight gain are associated with an increased risk of
developing kidney stones.
3. Diabetes
o Diabetes is a risk factor for the development of kidney stones.
o Insulin resistance may lead to altered acidification of the urine and
increased urinary calcium excretion.
4. Geographical factors
o The highest risk of developing kidney stones is in the south-
eastern United States; the lowest risk is in the northwestern United
States.

4-4-2016
4 ©Ali Kareem 2015-2016
o Stone incidence peaks approximately 1 to 2 months after highest
annual temperature.
PATHOPHYSIOLOGY OF STONE FORMATION
1. Idiopathic calcium oxalate
a. Approximately 70% to 80% of incident stones are calcium
oxalate.
b. Initial event is precipitation of calcium phosphate on the renal
papilla as Randall plaques, which serve as a nucleus for
calcium oxalate precipitation and stone formation.
c. Calcium oxalate stones preferentially develop in acidic urine
(pH less than 6.0).
d. Development depends on supersaturation of both calcium and
oxalate within the urine.
2. Idiopathic hypercalciuria
a. Identified in 30% to 60% of calcium oxalate stone formers and in
5% to 10% of nonstone formers
b. The upper limit of normal for urinary calcium excretion is 250
mg/day for women and 300 mg/day for men.
c. Need to exclude hypercalcemia, vitamin D excess, hyper-
thyroidism, sarcoidosis, and neoplasm.
d. Diagnosed via exclusion in patients with a normal serum calcium
but elevated urinary calcium on a random diet.
3. Absorptive hypercalciuria
a. Increased jejunal absorption of calcium possibly caused by
elevated calcitriol (1,25 dihydroxy vitamin D 3 ) levels and
increased vitamin D receptor expression.
b. Divided into type I, II and III, depending on whether urinary
calcium levels can be affected by calcium in the diet (type I and
II) or renal phosphate leak leading to increased calcium
absorption (type III).
c. Increased calcium absorption leads to a higher filtered load of
calcium delivered to the renal tubule.

4-4-2016
5 ©Ali Kareem 2015-2016
d. The treatment for each subtype is generally the same, so de-
termining which type (often requiring inpatient evaluation) is
no longer necessary.
e. Normal serum calcium
4. Renal hypercalciuria
a. Impaired proximal tubular reabsorption of calcium leads to
renal calcium wasting.
b. Normal serum calcium; hypercalciuria persists despite a
calcium restricted diet.
c. Distinguished from primary hyperparathyroidism by normal
serum calcium levels and secondary hyperparathyroidism.
5. Resorptive hypercalciuria
a. Primary hyperparathyroidism is the underlying mechanism.
b. Increased PTH levels cause bone resorption and intestinal
calcium absorption, which leads to elevated serum calcium that
exceeds the reabsorptive capacity of the renal tubule.
c. Normal to slightly elevated serum calcium
6. Hypercalcemic hypercalciuria
a. Primary hyperparathyroidism, hyperthyroidism, sarcoidosis,
vitamin D excess, milk alkali syndrome, immobiliza- tion, and
malignancy
7. Hyperoxaluria
a. The upper limit of normal for urinary oxalate excretion is 45 mg/d
in women and 55 mg/d in men.
b. Acts as a potent inhibitor of stone formation by complexing with
calcium
c. Dietary hyperoxaluria is related to increased consumption of
oxalate-rich foods, and/or a low-calcium diet, which by reducing
the availability of intestinal calcium to complex to oxalate, allows
an increased rate of free oxalate absorption by the gut.
d. Enteric hyperoxaluria can be caused by small bowel disease or
loss, exocrine pancreatic insufficiency, or diarrhea, all of which
reduce small bowel fat absorption, leading to an increase in fat

4-4-2016
6 ©Ali Kareem 2015-2016
complexing with calcium, and thereby facilitating free oxalate
absorption by the colon.
e. Primary hyperoxaluria is a genetic disorder in one of two genes,
which results in increased production or urinary excretion of
oxalate.
8. Hypocitraturia
a. The lower limit of normal is less than 500 mg/d for women and 350
mg/d for men.
b. Acts as an inhibitor of stone formation by complexing with
calcium.
c. Citrate is regulated by tubular reabsorption, and reabsorption
varies with urinary pH. In acidic conditions, tubular reabsorption
is enhanced, which lowers urinary citrate levels.
d. Diseases that cause acidosis, such as chronic diarrhea or distal
RTA, cause lower urinary citrate levels. Thiazide therapy can also
reduce citrate levels via potassium depletion.
e. In the majority of patients with hypocitraturia, no etiol- ogy is
identified, and these patients are classified as having idiopathic
hypocitraturia.
9. Hyperuricosuria/uric acid stones
a. Approximately 5% to 10% of incident stones are uric acid.
b. The upper limit of normal is greater than 750 mg/d for women and
800 mg/d for men.
c. Uric acid is a promoter for calcium oxalate stone formation by
serving as a nucleus for crystal generation and also by reducing
the solubility of calcium oxalate.
d. A low urinary pH is critical for uric acid stone formation. At a
urinary pH less than 5.5, uric acid exists in its insoluble
undissociated form, which facilitates uric acid stone formation. As
the urinary pH increases, the dissociated monosodium urate
crystals are predominant and serve as a nucleus for calcium-
containing stone formation.
e. Increased uric acid production is common in patients with a high
dietary intake of animal protein, in myeloprolifera- tive disorders,
and in gout. However, uric acid stone formation is also common

4-4-2016
7 ©Ali Kareem 2015-2016
in patients with diabetes and the metabolic syndrome presumably
caused by insulin resistance, which impairs renal ammonia
excretion necessary for urinary alkalization.
10. Cystinuria
a. In both men and women, urinary cystine excretion exceeds 350 mg/
d.
b. Caused by autosomal recessive disorder involving the SLC3A1
amino acid transporter gene on chromosome 2
c. The dibasic amino acid transporter, which is located within the
tubular epithelium, facilitates reabsorption of dibasic amino acids,
such as cystine, ornithine, lysine, and arginine, (COLA). A defect
in this enzyme leads to de- creased cystine reabsorption and
increased urinary excretion of cystine.
d. Cystine solubility rises with increasing pH and urinary volume.
e. Positive urine cyanide-nitroprusside colorimetric reaction is a
qualitative screen.
11. Calcium phosphate stones
a. Approximately 12% to 30% of incident stones are calcium
phosphate
b. Calcium phosphate stones preferentially develop in alkaline
urine (pH greater than 7.5).
c. Calcium phosphate stones can be present as either apatite or
brushite (calcium phosphate monohydrate).
d. Overalkalinization with potassium citrate for hypercalciuria can
sometimes lead to calcium phosphate stones.
12. Struvite stones/triple phosphate/infection stones
a. Approximately 5% of incident stones are struvite.
b. Struvite stones are composed of magnesium ammonium phosphate
and calcium phosphate. They may also contain a nidus of another
stone composition.
c. Often grow to encompass large areas in the collection system or
staghorn calculi.
d. Urinary tract infections (UTIs) with urease splitting organisms,
which include Proteus spp., Klebsiella spp., Staphylococcus

4-4-2016
8 ©Ali Kareem 2015-2016
aureus, Pseudomonas spp., and Ureaplasma spp., are required to
split urea into ammonia, bicarbonate, and carbonate.
e. A urinary pH greater than 7.2 is required for struvite stone
formation.
f. Conditions that predispose to urinary tract infections increase the
likelihood of struvite stone formation. Struvite stones are common
in patients with spinal cord injuries and neurogenic bladders.
Clinical Manifestations of Nephrolithiasis
A. Asymptomatic kidney stones are found in 8% to 10% of screening
populations undergoing a CT scan for unrelated reasons.
B. Pain is the most common presenting symptom in the majority of patients.
1. The stone produces ureteral spasms and obstructs the flow of
urine, which causes a resultant distention of the ureter,
pyelocalyceal system, and ultimately the renal capsule to produce
pain.
2. Renal colic is characterized by a sudden onset of severe flank
pain, which often lasts 20 to 60 minutes. The pain is paroxysmal,
and patients are often restless and unable to get comfortable.
3. Three main sites of anatomic narrowing or obstruction are within
the ureter: the ureteropelvic junction, the lumbar ureter at the
crossing of the iliac vessels, and the ureterovesical junction.
4. The location of pain generally correlates with these sites of
anatomic narrowing: the ureteropelvic junction produces classic
flank pain, the midureter at the level of the iliac vessels produces
generalized lower abdominal dis- comfort, and the ureterovesical
junction produces groin or referred testes/labia majora pain.
C. Associated nausea and vomiting are frequent. Fever and chills are
common with concomitant UTI.
D. Dysuria or strangury, which is the desire to void but with urgency,
frequency, straining, and small voided vol- umes, is possible with stones
located at the ureterovesical junction.

4-4-2016
9 ©Ali Kareem 2015-2016
DIFFERENTIAL DIAGNOSIS
o Pyelonephritis: Fever with associated flank pain Musculoskeletal pain:
Pain with movement
o Appendicitis: Right lower quadrant tenderness at McBurney point
Cholecystitis: Right upper quadrant tenderness with Murphy sign
o Colitis/diverticulitis: Left lower quadrant tenderness with GI symptoms
o Testicular torsion: Abnormal testicular exam with high-riding testicle
Ovarian torsion/ruptured ovarian cyst: Adnexal tenderness
Evaluation of Patients with Nephrolithiasis
1. General considerations
a. All patients in the acute phase of renal colic should have a history
and physical, a urinalysis, a urine culture if urinalysis
demonstrates bacteruria or nitrites, and a serum creatinine. If
the patient presents with fever, then a complete blood count should
also be included.
b. All patients with a first stone episode should undergo a basic
evaluation with a medical history including family history,
dietary history, and medications; physical exam and ultrasound;
blood analysis with creatinine, calcium, and uric acid; urinalysis
and culture; and stone analysis.

4-4-2016
10 ©Ali Kareem 2015-2016
c. Patients at high risk include those with a family history of
nephrolithiasis, recurrent stone formation, large stone burden,
residual stone fragments after therapy, solitary kidney, metabolic,
or genetic abnormalities known to predispose to stone formation,
stones other than calcium oxalate, and children given a higher rate
of an underlying metabolic, anatomic, and/or functional voiding
abnormality. These patients they should undergo the basic
evaluation, plus two 24-hour urine collections, at least 4 weeks
following the acute stone episode. Further therapy will be
guided by the stone analysis and 24-hour urine collections.
2. Medical history
a. General medical history is mandatory in all stone formers.
b. Past medical history with a specific focus on diseases known to
contribute to stone formation, including inflammatory bowel
disease, previous bowel resection, or gastric bypass,
hyperparathyroidism, hyperthyroidism, RTA, and gout.

4-4-2016
11 ©Ali Kareem 2015-2016
c. Family history is of particular importance because a positive
family history is a risk factor for incident stone formation and
recurrence.
d. Review medications for drugs known to increase stone formation,
such as acetazolamide, ascorbic acid, corticoste- roids, calcium-
containing antacids, triamterene, acyclovir, and indinavir.
e. Dietary history can also be relevant, especially in those with high-
or low-calcium diets, diets high in animal protein, and diets with
significant sodium intake.
3. Physical exam
a. May provide clues to underlying systemic diseases.
4. Laboratory evaluation
a. Urinalysis
1- Specific gravity may indicate relative hydration status.
2- Calcium oxalate stones preferentially form in a relatively
acidic pH (less than 6.0), whereas calcium phosphate stones
preferentially form in a relatively alkaline pH (greater than
7.5). A low pH (less than 5.5) is mandatory for uric acid
stone formation. A high pH (greater than 7.2) is critical for
struvite stone formation. A pH constantly greater than 5.8
may suggest an RTA.
o Microscopy may reveal red blood cells, white blood cells (WBCs), and
bacteria.
o Crystalluria can define stone type: Hexagonal crystals are cystine, coffin
lid crystals are calcium phosphate, and rhomboidal crystals are uric
acid.
b. Urine culture is mandatory if microscopy reveals bacte- riuria, if
struvite stones are suspected, or if symptoms or signs of infection
are present.
c. Electrolytes
1- Calcium (ionized or calcium with albumin): Elevated calcium
may suggest hyperparathyroidism, and a para- thyroid
hormone (PTH) blood test should be done.

4-4-2016
12 ©Ali Kareem 2015-2016
2- Uric Acid: Elevated uric acid is common in gout and, in
conjunction with a radiolucent stone, is suggestive of uric acid
nephrolithiasis.
d. A complete blood count (CBC) may show mild peripheral
leukocytosis. WBC counts higher than 15,000/mm 3 may suggest
an active infection.
e. Ammonium chloride load test: Identifies distal or Type I RTA.
Oral ammonium chloride load (0.1 gm/ kg body weight) given over
30 minutes will not raise the urinary pH greater than 5.4 if a Type
I RTA is present.
f. Sodium nitroprusside test: Identifies cystinuria. Addition of
sodium nitroprusside to urine with cystine concentration higher
than 75 mg/L alters the urine color to purple-red.
g. 24-Hour urine collection: Typically one to two 24- hour urine
collections are obtained at least 6 weeks after an acute stone event
or following initiation of medical therapy or dietary modification.
Collection is done to determine total urine volume, pH, creatinine,
calcium, oxalate, uric acid, citrate, magnesium, sodium,
potassium, phosphorus, sulfate, urea, and ammonia. Cystine is
also determined if a cystine screening test is positive.
Supersaturation indices are also calculated. An adequate
collection is determined by total creatinine, which is 15-19 mg/kg
for women and 20-24 mg/kg for men.
h. Stone analysis: Performed either with infrared spec- troscopy or
x-ray diffraction. It provides information about the underlying
metabolic, genetic, or dietary abnormality.
5. Imaging considerations
a. A noncontrast CT scan is the recommended initial imaging
modality for an acute stone episode. A noncontrast CT scan has a
sensitivity of 98% and a specificity of 97% in detect- ing ureteral
calculi. A low-dose noncontrast CT scan (less than 4 mSv) is
preferred in patients with a body mass index (BMI) less than 30.
When a ureteral stone is visualized on a noncontrast CT scan
b. A renal bladder ultrasound is the recommended initial imaging
modality in both children and pregnant patients in order to limit

4-4-2016
13 ©Ali Kareem 2015-2016
ionizing radiation. Ultrasonography has a median sensitivity of
61% and a specificity of 97%. If ultrasonography is equivocal,
and the clinical suspicion is high for nephrolithiasis, then a low-
dose noncontrast CT scan may be performed in both children and
pregnant patients.
c. Plain film of the kidneys, ureters, and bladder (KUB) is also
routinely used. Conventional radiography with a KUB has a
median sensitivity of 57% and a specificity of 76%. Pure uric acid,
cystine, indinavir, and xanthine stones are radiolucent, and are
not visible on KUB.
d. Intravenous pyelography (IVP) was commonly utilized for
diagnosis of stone disease because it could read- ily identify
radiolucent stones and define calyceal anatomy. It has a median
sensitivity of 70% and a specificity of 95%. However, CT has
largely replaced IVP.
e. Magnetic resonance imaging is generally not performed for
urolithiasis because of cost, low sensitivity, and time needed to
acquire images.
f. A combination of ultrasonography and KUB is recommended for
monitoring patients with known radiopaqueureteral calculi on
medical expulsion therapy because this limits costs and radiation
exposure. Those with radiolucent stones will require a low-dose
noncontrast CT scan.
Management of Nephrolithiasis
MEDICAL THERAPY
1. All stone formers
a. High fluid intake of 2.5-3.0 L/day with urine volume greater
than 2 L/ day
b. Normal calcium diet of 800-1200 mg/day, preferably not
through supplements. Avoid excess calcium supplementation;
however calcium citrate is preferred if indicated.
c. Limit sodium to 4-5 g/day.

4-4-2016
14 ©Ali Kareem 2015-2016
d. Limit animal protein to 0.8-1.0 g/kg/day.
e. Limit oxalate-rich foods.
f. Maintain a normal BMI and physical activity.
g. Targeted therapy depending on underlying metabolic ab-
normality and/or 24-hour urine collection results
2. Calcium oxalate stones
a. Dietary hyperoxaluria: Limit oxalate-rich foods.
b. Enteric hyperoxaluria: Limit oxalate-rich foods and calcium
supplementation with greater than 500 mg/day.
c. Primary hyperoxaluria: Pyridoxine can decrease endog- enous
production of oxalate. The dose is 100-800 mg/day.
d. Hypocitraturia: Potassium citrate both raises the urinary pH out
of the stone-forming range and restores the normal urinary citrate
concentration. Sodium bicarbonate may also be used, if unable to
tolerate potassium supplementation.
e. Hypercalciuria: Thiazide diuretics, which inhibit a sodium-
chloride co-transporter, therefore enhancing distal tubular sodium
reabsorption via the sodium-calcium co-transporter to promote
tubular calcium reabsorption. Thiazides decrease urinary
calcium by as much as 150 mg/day.
3. Calcium phosphate stones
a. Primary hyperparathyroidism: Requires parathyroidectomy.
b. Distal RTA (Type I): Potassium citrate or sodium bicarbonate to
restore the natural pH balance.
4. Struvite/infection stones
a. Total stone removal because each fragment harbors urease-
producing bacteria and serves as a nidus for further stone growth.
b. Appropriate antibiotic therapy to eradicate the urease-producing
bacteria
c. Restoration of normal pH with urinary acidification with L-
methionine or inhibition of urease enzyme with acetohy- droxamic
acid
5. Uric acid stones
a. Low animal protein diet
b. Specific therapy depends on 24-hour urine collection results.

4-4-2016
15 ©Ali Kareem 2015-2016
c. Alkalinization of the urine with potassium citrate or sodium
bicarbonate for stone dissolution is possible with a pH of 7.0 to
7.2 and for maintenance of a stone-free state with a pH of 6.2 to
6.8.
d. Hyperuricosuria (with or without hyperuricemia): Allopurinol at
100-300 mg/day, which inhibits xanthine oxidase to reduce uric
acid production.
6. Cystine stones
a. Increase daily fluid intake to 3.5 to 4.0 L/day.
b. Specific therapy depends on 24-hour urine collection results.
c. Alkalinization of the urine with potassium citrate or sodium
bicarbonate above a pH of 7.5 to improve solubility of cystine
threefold
d. d. D-penicillamine is a chelating agent that forms a disulbond
with cysteine to produce a more soluble compound, thereby
preventing the formation of cysteine into the insoluble, stone
forming, cystine. Alpha-mercaptopropionyl-glycine (tiopronin) is
the preferred alternative to D-penicillamine, as it has a better
safety and efficacy profile. Alpha- mercaptopropionyl-glycine
reduces the disulfide bond of cystine to form the more soluble
cysteine, again reducing stone formation. Lastly, captopril is an
angiotensin-converting enzyme inhibitor, which can reduce
cystine, but its role in therapy is not yet well defined.
ACUTE RENAL COLIC
1. General considerations
a. Primary considerations include symptomatic control with
analgesics, antiemetics, and adequate hydration.
b. First-line analgesia is generally a nonsteroidal antiinflam-
matory, such as ketorolac.
c. Patients should be instructed to sieve their urine for collection of
stone fragments.

4-4-2016
16 ©Ali Kareem 2015-2016
d. Spontaneous stone passage occurs in 80% of patients with sizes
less than 4 mm. With sizes greater than 10 mm, there is a low
probability of spontaneous passage.
e. Referral to a urologist is necessary with persistent pain, high-
grade obstruction, bilateral obstruction, presence of infection,
solitary kidney, abnormal anatomy, failure of conservative
management, large stone burden, pregnancy, or in children.
2. Medical expulsive therapy
a. Alpha-blockers, such as tamsulosin, and calcium channel blockers
(nifedipine) or steroids can facilitate stone passage via ureteral
smooth muscle relaxation.
b. Medical expulsive therapy (MET) is acceptable in patients with
ureteral calculi less than 10 mm who have well- controlled pain,
no evidence of infection, adequate renal function, and no other
contraindications to the therapy.
SURGICAL THERAPY
1. Shock wave lithotripsy (SWL):
a. Shock waves are high-energy focused-pressure waves that can travel
in air or water. When passing through two different mediums of
different acoustic impedance, energy is released, which results in the
fragmentation of stones. Shock waves travel harmlessly through
substances of the same acoustic density. Because water and body
tissues have the same density, shock waves can travel safely through
skin and internal tissues. The stone is a different acoustic density and,
when the shock waves hit it, they shatter and pulverize it. Urinary
stones are thus fragmented, facilitating in their spontaneous passage.
b. Treatment success depends on stone size, location, composition,
hardness, and body habitus. For renal stones, upper or middle polar
stones are ideally treated with SWL, whereas lower pole stones have
a clearance rate as low as 35%.
c. Ideally all stones less than 1 cm in any location in the kidney can be
treated with SWL.

4-4-2016
17 ©Ali Kareem 2015-2016
d. Contraindications of SWL include (absolute) pregnancy, bleeding
diathesis, and obstruction below the level of the stone; and (relative)
calcified arteries and/or aneurysms and cardiac pacemaker.
e. Complications of SWL include skin bruising, subscapular and
perinephric hemorrhage, pancreatitis, urosepsis, and Steinstrasse
(“street of stone,” which may accumulate in the ureter and cause
obstruction).
2. Percutaneous nephrolithotomy (PCNL)
a. a. The technique is establishment of access at a lower pole ca- lyx,
dilation of the tract with a balloon dilator or Amplatz dilators
under fluoroscopy, and stone removal with grasp- ers or its
fragmentation using electrohydraulic, ultrasonic, or laser
lithotripsy. A nephrostomy tube or ureteral stent is left for
drainage.
b. d. Additional candidates for PCNL include cystine calculi, which
are large volume and resistant to SWL, and anatomic
abnormalities, such as those with ureteropelvic junction (UPJ)
obstruction, caliceal diverticula, obstructed infundib- ula
(hydrocalyx), ureteral obstruction, malformed kidneys (e.g.,
horseshoe and pelvic), and obstructive or large adjacent renal
cysts.
c. e. Contraindications of PCNL include uncontrolled bleeding
diathesis, untreated urinary tract infection (UTI), and in- ability to
obtain optimal access for PCNL because of obesity,
splenomegaly, or interposition of colon.
d. f. Complications of PCNL include hemorrhage (5% to 12%),
perforation, and extravasation (5.4% to 26%), damage to adjacent
organs (1%), ureteral obstruction (1.7% to 4.9%), and
infection/urosepsis (3%).
3. Retrograde intrarenal surgery (ureteroscopy [URS])
a. Instrumentation includes both rigid and flexible ureteroscopes.
Rigid ureteroscopes are ideally suited for access to the distal
ureter but can be utilized up to the proximal ureter. Flexible
ureteroscopes are ideally suited for ureteral and intrarenal
access.

4-4-2016
18 ©Ali Kareem 2015-2016
b. URS may be safely performed in patients with morbid obesity,
pregnancy, and bleeding diathesis.
c. Complications include failure to retrieve the stone, muco- sal
abrasions, false passages, ureteral perforation, complete ureteral
avulsion, and ureteral stricture.
4. Open/laparoscopic/robotic surgery
a. Since the introduction of minimally invasive techniques such as
SWL, URS, and PCNL, open surgery has been reduced to rates
of 1% to 5%.
b. Indications for open stone surgery include complex stone burden,
treatment failure with endoscopic techniques, anatomic
abnormalities, and a nonfunctioning kidney.
c. Laparoscopic or robotic surgery can be used in place of open
techniques, but because of the complexity and rarity of these
procedures, they are generally referred to centers of excellence.
END OF THIS LECTURE …

Lec. 1+2 - Nephrolithiasis.pdf

More Related Content

Similar to Lec. 1+2 - Nephrolithiasis.pdf

Recently uploaded

Lec. 1+2 - Nephrolithiasis.pdf